Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RA) not only significantly lower blood glucose but also reduce multiple cardiovascular risk factors. Moreover, some of this class of anti-diabetic drugs have been shown to have beneficial effects in cardiovascular outcome trials. This expert consensus is developed for the optimal use of GLP-1RA in individualized treatment of type 2 diabetes mellitus (T2DM) and includes the timing of GLP-1RA use in the glucose-lowering therapeutic algorithm, the precautions while combined with other anti-diabetic drugs, the therapeutic benefits while preferably added on the anti-diabetic therapies for patients with T2DM and atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD), and the use of GLP-1RA in special population of patients with T2DM.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.